Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
Date:10/31/2007

arbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including: limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-K, 10-Q, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Apollos human proteins boost stem cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...uly 24 /- Alexza,Pharmaceut...it has initiated,its second Phase 3 clinical trial...inhalation product candidate being developed for t...chizophrenia or bipolar disorder.,Alexza believes ...inetic,(PK) properties resulting from inhaled loxa...
(Date:7/24/2008)...Program Speeds Oncology Patient Accrual, DENVER, ...ch Management,Organization (RMO), has contracted w...de research and site management services for their...llment strategy. The new,trials include the follow...Lymphoma, Metastatic Breast Cancer, Metastatic Sar...
(Date:7/24/2008)..., July 24 /- NicOx S.A.,(Eu...sults from the 52-week,open label safety extension...e 301 phase 3 study for naproxcinod. The results r... was maintained for the one-year duration of,the s...nt scale. In,addition, the results showed that the...
(Date:7/23/2008)...wire/ -- Sound Pharmaceuticals (SPI) has filed,an ...for the clinical,testing of a proprietary formulat...induced hearing loss or ototoxicity. The oral caps...n advanced stage lung cancer,and head and neck can....,This marks the second development program for SP...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2K State Preparing to Share Expertise With Bioscientists 3601 1K State Preparing to Share Expertise With Bioscientists 3601 24th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 14th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 24th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 34th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 4Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 1Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 2Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 3Ginkgo Biloba Might Not Preserve Memory in Octogenarians 13049 1Ginkgo Biloba Might Not Preserve Memory in Octogenarians 13049 2Ginkgo Biloba Might Not Preserve Memory in Octogenarians 13049 3
...wire-FirstCall/ --,Bionovo, Inc. will present find... agent BZL101, which is advancing to Phase 1/2,cli...American,Association of Cancer Research (AACR) bei...s Angeles, CA, April 14 - 17, 2007. , Bionovo,s po...ncer cell apoptosis (cell death) induced by BZL101...
...vity, a Novel Mechanism,of Action and In Vitro Com...Conn., April 16, 2007 /PRNewswire-FirstCall/ --,Ac...presentation of,data validating the clinical antiv...ts, ACH-806, for the treatment of,hepatitis C viru...e,European Association for the Study of the Liver ...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:7/25/2008)... Though the number of jobs created in the me...es reported a different kind of slowdown: they lai.... , Seattle, WA (PRWEB) J...in the medical field slowed in June overall, pharm...lowdown that will be music to the ears of sales re...
(Date:7/25/2008)...rporation Executive, Robert J. Reilly, Joins Aetho...n Inc.,( http://www.aethon.com ), the leading deve... logistics, today announced that Robert J. Reilly ... Chief Financial Officer., Reilly, who was most r...sson Corporation,s Specialty Pharmacy Division, br...
(Date:7/25/2008)...ack-up in esophagus can cause immune system change...- The first evidence linking gastroesophageal refl...y Duke University Medical Center researchers. ,...st noted in the 1970s, and since then studies have...sthma patients also experience GERD symptoms. But ...
(Date:7/25/2008)... The Drug Information Association (DIA) and ...he Critical Path Initiative (CPI) on the Move: Com...da, MD) and the Critical Path Transporter Workshop... Horsham, PA (PRWEB) July 25, 2005-- T...ociation (DIA)] and the Food and Drug Administrati...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...Researchers have uncovered important information a...zed DNA, a critical step in DNA mutation that has ...at appears in the August edition of the Journal of... Georgia Institute of Technology have reported unc...
...The cells and receptors responsible for sour taste...titute researcher Charles S. Zuker and Nicholas J....er seven years of working together to identify the...r three of the five tastes humans can sense -- swe...
...Aromatherapy, the treatment using scents, is one o...ne. It is a holistic treatment of caring for the ...t is widely used at home, clinics and hospitals fo...in relief for women in labor pain, relieving pain ...
...The Beijing Health Bureau confirmed on Friday the .... About 3,142 HIV carriers and AIDS patients were...ing according to Statistics from the Beijing Healt...re discovered in the first six months of the year....
Other Medicine News:Health News:Elusive Step In DNA Mutation Uncovered By Researchers 2Health News:Elusive Step In DNA Mutation Uncovered By Researchers 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 4Health News:Sour Taste Sensors Identified 2Health News:Sour Taste Sensors Identified 3Health News:Benefits Of Aromatherapy 2Health News:Benefits Of Aromatherapy 3Health News:Benefits Of Aromatherapy 4
Portable Compressor Nebulizer
The 50 psi MaxiCompressor, the workhorse of compressors, is designed to run 24 hours a day, 7 days a week. It features a tamper-proof locking regulator valve to guard against unintentional increases
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel
The very popular and competitively priced SportNeb features a 35 PSI, die-cast aluminum compressor. Design enhancements include a neb kit holder, built-in cord storage and optional black carry bag. T
Medicine Products: